• Psyched Wellness (PSYC) has released preliminary data from its study with the National Research Council of Canada
  • The study has confirmed that the company’s key proprietary extract, AME-1, holds anti-inflammatory properties
  • Psyched Wellness is developing AME-1 into water-based extracts to help promote stress relief, relaxation, and restful sleep
  • Psyched Wellness is a Canadian life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms
  • Shares in Psyched Wellness Corp. (PSYC) are up 4.76 per cent, trading at $0.11 per share

Psyched Wellness (PSYC) has released preliminary data from its study with the National Research Council of Canada (NRC).

Psyched engaged the NRC to provide their expertise in biomedical nanotechnology for the study.

The study has confirmed that the company’s key proprietary extract, AME-1, holds anti-inflammatory properties.

AME-1 is extracted from the Amanita Muscaria mushroom, which Psyched Wellness is developing into water-based extracts to help promote stress relief, relaxation, and restful sleep.

The study is examining the anti-inflammatory properties of AME-1 by studying the effects of the extract on mast cells, which are important inflammatory cells present in the skin, gut, brain, and lungs.

Prior research performed by the NRC had already shown that AME-1 inhibited mast cell activation of histamine release.

This continued research has verified that pre-treatment of human mast cells with AME-1 results in the decrease of the release of pro-inflammatory mediators such as inflammatory cytokines.

“We are excited about these findings and the potential they may have to help sufferers of conditions such as arthritis,” remarked Jeff Stevens, CEO of Psyched Wellness. “We look forward to sharing more updates as additional studies are undertaken to further examine the mechanisms of the anti-inflammatory properties of the Amanita Muscaria mushroom.”

Psyched Wellness is a Canadian life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms.

Shares in Psyched Wellness Corp. (PSYC) are up 4.76 per cent, trading at $0.11 per share as of 12:20 pm EST.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.